The ACR has long supported efforts to reduce drug prices through many of the provisions included in the House-passed version of the Build Back Better Act. However, the current wording of one provision puts patient access to Medicare Part B treatments at risk.
NEW YORK (Reuters Health)—In patients with psoriatic arthritis (PsA) who are resistant to tumor necrosis factor inhibitors (TNFi), guselkumab was more effective than placebo in a phase 3b trial. “Guselkumab is a relatively new treatment and is the first drug in its class (IL-23 inhibitor) to gain approval for PsA,” Dr. Laura Coates of the…
NEW YORK (Reuters Health)—Tofacitinib significantly reduces the number of flares in children with polyarticular course juvenile idiopathic arthritis (JIA), according to the first phase-3 clinical trial to assess the efficacy of a Janus kinase (JAK) inhibitor in JIA. JIA is a heterogeneous group of chronic conditions with no known cause that develop before age 16…
NEW YORK (Reuters Health)—In patients with knee osteoarthritis (OA), telehealth-delivered exercise and diet programs are superior to electronic health information for reducing pain and improving function, although the contribution of diet is modest, a randomized trial shows.1 “This research provides evidence from a large clinical trial to help tease out how much benefit dietary weight…
The diverse topics, research & perspectives from this year’s ACR Convergence bring new insights for rheumatologists & all who care for their patients, according to speakers at the meeting’s Closing Session.
The ACR highlights essential information for providers for 2022 MIPS reporting in the 2022 Medicare Physician Fee Schedule Final Rule, published Nov. 2.
Options to escalate treatment for refractory inflammatory myositis and new therapies in the pipeline are discussed.
ACR CONVERGENCE 2021—Many of the effects of childhood-onset systemic lupus erythematosus (cSLE) and vasculitis carry into adulthood and present adult rheumatologists with key differences in managing these patients after their transition from a pediatric to an adult provider. “The young adult with childhood-onset lupus is similar in many ways to adults with lupus, but there…
Mara L. Becker, MD, MSCE, discusses how important it is to effectively treat juvenile idiopathic arthritis at an early stage to improve long-term outcomes in adulthood.
Two experts described the measurements of disease activity used in axial spondyloarthritis and psoriatic arthritis and how rheumatologists can apply them in practice.